levodopa · Merz · NDA 209184
Inbrija
Earliest generic entry, as listed
21 Oct 2033
Blocked by patent: US 12458615. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 6 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 12458615 | use U-2484 | 21 Oct 2033 |
| US 8545878 | product | 16 Nov 2032 |
| US 8685442 | product | 16 Nov 2032 |
| US 8945612 | product | 16 Nov 2032 |
| US 9393210 | product | 16 Nov 2032 |
| US RE43711 | use U-2484 | 3 Feb 2029 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 209184 · 001 · RLD | powder, inhalation | 42MG | 21 Oct 2033 |